Literature DB >> 2144556

Late effects associated with treatment of craniopharyngiomas in childhood.

T Shiminski-Maher1, M Rosenberg.   

Abstract

Craniopharyngiomas are the most common pediatric suprasellar tumor. They are clinically slow growing tumors whose primary treatment is surgical resection. Because of their location in the brain, craniopharyngiomas are associated with both acute and chronic problems including endocrinopathies and visual, neuropsychological and psychosocial dysfunctions. Fifteen patients and families of children operated upon at New York University Medical Center over the past twenty years indicated through interviews that all had significant sequelae associated with their illness. Nursing management of these problems during the acute and chronic phases of the illness will be discussed.

Entities:  

Mesh:

Year:  1990        PMID: 2144556     DOI: 10.1097/01376517-199008000-00006

Source DB:  PubMed          Journal:  J Neurosci Nurs        ISSN: 0888-0395            Impact factor:   1.230


  4 in total

Review 1.  Pediatric Craniopharyngiomas: A Primer for the Skull Base Surgeon.

Authors:  Christopher Salvatore Graffeo; Avital Perry; Michael J Link; David J Daniels
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-19

2.  Treatment factors associated with outcomes in children less than 3 years of age with CNS tumours.

Authors:  Catherine Ward; Kim Phipps; Carlos de Sousa; Stephen Butler; Dianne Gumley
Journal:  Childs Nerv Syst       Date:  2009-02-27       Impact factor: 1.475

3.  Trans-eyebrow supraorbital keyhole approach in suprasellar and third ventricular craniopharyngioma surgery: the experience of 27 cases and a literature review.

Authors:  Meiqin Cai; Zhuopeng Ye; Cong Ling; Baoyu Zhang; Bo Hou
Journal:  J Neurooncol       Date:  2018-11-03       Impact factor: 4.130

Review 4.  Prevalence of neurobehavioral, social, and emotional dysfunction in patients treated for childhood craniopharyngioma: a systematic literature review.

Authors:  Gabriel Zada; Natalie Kintz; Mario Pulido; Lilyana Amezcua
Journal:  PLoS One       Date:  2013-11-05       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.